

08-02-2007

Client Code: ABXAZ.004A




103432883

To the Director, U.S. Patent and Trademark Office

original documents or copy thereof.

6.29.07

<p>1. Name of conveying party(ies): (List using letters or numbers for multiple parties)  <b>AMGEN FREMONT INC.</b></p> <p>Additional name(s) of conveying party(ies) attached?  <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>	<p>2. Name and address of receiving party(ies):  <b>Name: ASTRAZENECA AB</b>  <b>Street Address: SE-151 85</b>  <b>City: SÖDERTÄLJE</b>  <b>Country: SWEDEN</b></p> <p>Additional name(s) of receiving party(ies) attached?  <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>3. Nature of conveyance:  <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Security Agreement  <input type="checkbox"/> Merger <input type="checkbox"/> Change of Name  <input type="checkbox"/> Other:</p> <p>Execution Date: (List as in section 1 if multiple signatures)    April 25, 2007</p>	<p>4. US or PCT Application number(s) or US Patent number(s):  <input checked="" type="checkbox"/> Patent Application No.: 11/608,705  Filing Date: December 8, 2006</p> <p>Additional numbers attached?  <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>5. Party to whom correspondence concerning document should be mailed:    <b>Customer No. 20,995</b>  <b>Address: Knobbe, Martens, Olson &amp; Bear, LLP</b>  2040 Main Street, 14<sup>th</sup> Floor  Irvine, CA 92614  <b>Return Fax: (949) 760-9502</b>  <b>Attorney's Docket No.: ABXAZ.004A</b></p>	<p>6. Total number of applications and patents involved: <b>13</b></p>
<p>7. Total fee (37 CFR 1.21(h)): <b>\$120-</b>  <input checked="" type="checkbox"/> Authorized to be charged to deposit account</p>	<p>8. Deposit account number: 11-1410  Please charge this account for any additional fees which may be required, or credit any overpayment to this account.</p>
<p>9. Statement and signature.  To the best of my knowledge and belief, the foregoing information is true and correct, and any attached copy is a true copy of the original document.</p> <p><b>Brent C. Moore</b>  Name of Person Signing  Signature <u>June 29, 2007</u> Date</p> <p><b>55,461</b>  Registration No.</p> <p>Total number of pages including cover sheet, attachments and document: 7</p>	

CH \$120.00 111410 11608705

Documents transmitted via Facsimile to be recorded with required cover sheet information to:

Mail Stop Assignment Recordation Services  
Director, U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
Facsimile Number: (571) 273-0140

3945659\cey  
062907

**RECORDATION FORM COVER SHEET (CONTINUED)**

**SECTION 4 (CONTINUED)**

US or PCT Application number(s) or US Patent number(s):

- (X) Patent Application No.: 60/835,559  
Filing Date: August 3, 2006  
Attorney's Docket No.: ABXAZ.006PR
- (X) Patent Application No.: 60/835,647  
Filing Date: August 3, 2006  
Attorney's Docket No.: ABXAZ.007PR

PATENT

Page 1

**ASSIGNMENT**

WHEREAS, Amgen Fremont Inc., a Delaware corporation having offices at 6701 Kaiser Drive, Fremont, CA 94555 (hereinafter "ASSIGNOR"), represents and warrants that it has an ownership interest to certain new and useful improvements for which ASSIGNOR has filed the following United States applications for Letters Patents in the United States (hereinafter "the Patent Applications"):

TITLE	APPLICATION NO.	FILING DATE
ANTIBODIES DIRECTED TO MONOCYTE CHEMO-ATTRACTANT PROTEIN- 1 (MCP-1) AND USES THEREOF	10/644,277	August 19, 2003
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	11/311,939	December 19, 2005
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	11/440,728	May 25, 2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	11/608,705	December 8, 2006
ANTIBODIES DIRECTED TO aVB6 AND USES THEREOF	60/835,559	August 3, 2006
ANTIBODIES DIRECTED TO PDGFR-ALPHA AND USES THEREOF	60/835,647	August 3, 2006

WHEREAS, AstraZeneca AB, a Swedish corporation having offices at Södertälje, SE - 151 85, Sweden (hereinafter "ASSIGNEE") desires to purchase the ASSIGNOR'S entire right, title, and interest in and to the inventions disclosed in the Patent Applications;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby further acknowledges that it has sold, assigned, and transferred, and by these presents does hereby sell, assign, and transfer, unto ASSIGNEE, its successors, legal representatives, and assigns, its entire right, title, and interest throughout the world in, to, and under the said improvements, and the said Patent Applications and all Patents that may be granted thereon, and all provisional applications relating thereto, and all divisions, continuations, reissues, reexaminations, renewals, and extensions thereof, and all rights of priority under International Conventions and applications for Letters Patent that may hereafter be filed for said improvements or for the said Patent Applications in any country or countries foreign to the United States, including but not limited to those in Attachment A; and ASSIGNOR hereby authorizes and requests the Commissioner of Patents of the United States, and any Official of any country foreign to the United States, whose duty it is to issue patents on applications as aforesaid, to issue all Letters Patent for said improvements and all Letters Patents resulting from the Patent Applications to ASSIGNEE, its successors, legal representatives, and assigns, in accordance with the terms of this Agreement.

PATENT

REEL: 019654 FRAME: 0973

PATENT  
Page 2

ASSIGNOR does hereby sell, assign, transfer, and convey to ASSIGNEE, its successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to ASSIGNEE, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of the said Patents before or after issuance;

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 25<sup>th</sup> day of April, 2007.

Amgen Fremont Inc.

By: Stuart L. Watt



Name Printed: Stuart L. Watt

Title: Vice President, Law

Date: \_\_\_\_\_

STATE OF California }  
COUNTY OF Ventura } ss.


On April 25, 2007 before me, Karen E. Podgorny, notary public, personally appeared + personally known to me (or proved to me on the basis of satisfactory evidence) to be the person(s) whose name(s) is/are subscribed to the within instrument, and acknowledged to me that they executed the same in their authorized capacity(ies), and that by their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

[SEAL]

Karen E. Podgorny  
Notary Signature

3452868\lcey  
022107



PATENT  
Page 3

**ATTACHMENT A**

<b>Title of Invention:</b>	<b>Country:</b>	<b>Application No.</b>	<b>Filing Date:</b>
ANTIBODIES DIRECTED TO MONOCYTE CHEMO-ATTRACTANT PROTEIN-1 (MCP-1) AND USES THEREOF	AU	2003265575	8/19/2003
ANTIBODIES DIRECTED TO MONOCYTE CHEMO-ATTRACTANT PROTEIN-1 (MCP-1) AND USES THEREOF	CA	2496419	8/19/2003
ANTIBODIES DIRECTED TO MONOCYTE CHEMO-ATTRACTANT PROTEIN-1 (MCP-1) AND USES THEREOF	EP	03788686.8	8/19/2003
ANTIBODIES DIRECTED TO MONOCYTE CHEMO-ATTRACTANT PROTEIN-1 (MCP-1) AND USES THEREOF	HK	05110530.1	8/19/2003
ANTIBODIES DIRECTED TO MONOCYTE CHEMO-ATTRACTANT PROTEIN-1 (MCP-1) AND USES THEREOF	JP	2004-529174	8/19/2003
ANTIBODIES DIRECTED TO MONOCYTE CHEMO-ATTRACTANT PROTEIN-1 (MCP-1) AND USES THEREOF	WO	PCT/US2003/026232	8/19/2003
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	AR	P050105364	12/20/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	BD	333/2005	12/20/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	CL	3372-2005	12/21/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	MT	3190	12/20/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	MY	PI20056013	12/19/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	WO	PCT/US2005/045657	12/19/2005

**PATENT**  
Page 4

<b>Title of Invention:</b>	<b>Country:</b>	<b>Application No.</b>	<b>Filing Date:</b>
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	PK	1234/2005	12/20/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	SA	05260427	12/21/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	TH	107272	12/20/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	TW	094145705	12/21/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	UY	29288	12/21/2005
ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	VE	02665	12/21/2005
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	AR	P060102294	6/1/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	CL	1347-2006	6/2/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	MT	3513	5/30/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	MY	PI20062516	5/31/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	WO	PCT/US2006/020408	5/25/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	PK	556/2006	5/30/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	SA	06270159	6/3/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	TH	0601002467	5/31/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	TW	095119438	6/1/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	UY	29573	6/1/2006
ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	VE	01225-2006	6/2/2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	AR	P060105469	12/12/2006

PATENT  
Page 5

<b>Title of Invention:</b>	<b>Country:</b>	<b>Application No.</b>	<b>Filing Date:</b>
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	CL	2006-3507	12/13/2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	GC	GCC/P/2006/7409	12/13/2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	MT	3941	12/7/2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	WO	PCT/US2006/047059	12/8/2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	PK	1605/2006	12/5/2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	TH	0601006183	12/12/2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	TW	095146733	12/13/2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	UY	30.002	12/11/2006
BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOF	VE	02891-2006	12/13/2006